CorMedix targets $45M-$60M in annual synergies as it expects Heron assets to add $125M-$150M in pro forma 2027 revenue
CorMedix targets $45M-$60M in annual synergies as it expects Heron assets to add $125M-$150M in pro forma 2027 revenue(摘要待生成)
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research(摘要待生成)
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research(摘要待生成)
CorMedix (CRMD) Q3 2026 Earnings Call Transcript
CorMedix (CRMD) Q3 2026 Earnings Call Transcript(摘要待生成)
CorMedix: Q3 Earnings Snapshot - Yahoo Finance
CorMedix: Q3 Earnings Snapshot - Yahoo Finance(摘要待生成)
CorMedix Shares Decline Following DaVita Commentary on DefenCath Reimbursement
CorMedix shares reached a 52-week low after DaVita's CFO indicated that Medicare add-on payments for the DefenCath catheter lock solution are expected to decline significantly starting in the second quarter of 2027.
DaVita Inc. 3rd Quarter 2026 Results
DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026:... The post DaVita Inc. 3rd Quarter 2026 Results appeared first on Investor.